Viral Inactivation Market Size, Share, Growth Analysis, By Method (Solvent Detergent Method, Pasteurization), By Product (Kits and Reagents, Services), By Application, By End User, By Region - Industry Forecast 2025-2032
세계의 바이러스 불활성화 시장 규모는 2023년에 6억 237만 달러로 평가되며, 2024년 6억 7,646만 달러에서 2032년에는 17억 1,112만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 12.3%로 성장할 전망입니다.
세계 바이러스 불활성화 시장은 제약, 생명공학, 헬스케어 분야에서 효과적인 바이러스 제거에 대한 수요 증가에 힘입어 크게 확대될 것으로 예상됩니다. 바이오의약품의 생산이 증가함에 따라 생물제제, 백신, 치료제에서 감염 요인을 제거하기 위한 엄격한 바이러스 안전 조치가 필요하며, FDA 및 EMA와 같은 기관의 규제 준수는 매우 중요하며, 기업은 오염 위험을 줄이기 위해 견고한 기술로 전환하고 있습니다. 하고 있습니다. 바이오 제조 분야에서 일회용 기술의 채택이 증가함에 따라 안전성과 효율성이 향상되는 한편, 이 분야의 아웃소싱이 증가함에 따라 조사 업무를 전문으로 하는 위탁 기관에 대한 수요가 증가하고 있습니다. 지속적인 기술 발전과 안전에 대한 강조로 인해 시장은 혁신적인 솔루션과 전략적 파트너십을 위한 충분한 기회를 제공하고 공중 보건 문제 속에서 지속적인 성장을 보장하고 있습니다.
목차
서론
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요의 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
바이러스 불활성화 시장 규모 : 방법별
- 시장 개요
- 용제 세제법
- 살균법
- 기타 바이러스 불활성화법
바이러스 불활성화 시장 규모 : 제품별
- 시장 개요
- 키트와 시약
- 서비스
- 바이러스 불활성화 시스템과 부속품
바이러스 불활성화 시장 규모 : 용도별
- 시장 개요
- 혈액 및 혈액 제품
- 세포·유전자 치료 제품
- 줄기세포 제품
- 티슈 및 티슈 제품
- 백신과 치료제
바이러스 불활성화 시장 규모 : 최종사용자별
- 시장 개요
- 제약·바이오테크놀러지 기업
- 계약 조사기관
- 학술 조사기관
- 기타 최종사용자
바이러스 불활성화 시장 규모
- 북미
- 유럽
- 독일
- 스페인
- 프랑스
- 영국
- 이탈리아
- 기타 유럽 지역
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 개요
- 회사 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 매출의 전년대비 비교(2022-2024년)
주요 기업 개요
- Merck KGaA(Germany)
- Sartorius AG(Germany)
- Charles River Laboratories International, Inc.(United States)
- Parker Hannifin Corporation(United States)
- Thermo Fisher Scientific Inc.(United States)
- Bio-Rad Laboratories, Inc.(United States)
- Mettler-Toledo International Inc.(United States)
- SGS SA(Switzerland)
- WuXi AppTec Co., Ltd.(China)
- Lonza Group AG(Switzerland)
- Pfizer Inc.(United States)
- GE HealthCare Technologies Inc.(United States)
- Danaher Corporation(United States)
- Cerus Corporation(United States)
- Terumo BCT, Inc.(United States)
- Eurofins Scientific SE(Luxembourg)
- Macopharma SA(France)
- Kedrion S.p.A.(Italy)
- Rad Source Technologies, Inc.(United States)
결론과 권장사항
KSA
Global Viral Inactivation Market size was valued at USD 602.37 million in 2023 and is poised to grow from USD 676.46 million in 2024 to USD 1711.12 million by 2032, growing at a CAGR of 12.3% during the forecast period (2025-2032).
The global viral inactivation market is set for significant expansion, driven by a rising demand for effective viral clearance in pharmaceuticals, biotechnology, and healthcare. The increasing production of biopharmaceuticals necessitates stringent viral safety measures to eliminate infectious agents from biological products, vaccines, and therapeutics. Regulatory compliance from organizations like the FDA and EMA is crucial, pushing companies toward robust techniques to reduce contamination risks. The growing adoption of single-use technologies in biomanufacturing enhances safety and efficiency, while the rise in outsourcing within these sectors boosts demand for contract research organizations specializing in viral inactivation services. With ongoing technological advancements and a focus on safety, the market offers ample opportunities for innovative solutions and strategic partnerships, ensuring sustained growth amid public health concerns.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viral Inactivation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Viral Inactivation Market Segmental Analysis
Global Viral Inactivation Market is segmented by Method, Product, Application, End User and region. Based on Method, the market is segmented into Solvent Detergent Method, Pasteurization and Other Viral Inactivation Method. Based on Product, the market is segmented into Kits and Reagents, Services and Viral Inactivation Systems and Accessories. Based on Application, the market is segmented into Blood & Blood Products, Cellular & Gene Therapy Products, Stem Cell Products, Tissue & Tissue Products and Vaccines and Therapeutics. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Viral Inactivation Market
The Global Viral Inactivation market is significantly influenced by advancements in the biopharmaceutical sector, particularly in the development of monoclonal antibodies, gene therapies, and personalized medicine. As the production of intricate biologics and innovative therapies expands, the necessity for reliable viral inactivation techniques intensifies in order to safeguard the integrity and safety of these treatments. This growing demand is further fueled by stringent regulatory requirements and a heightened focus on delivering high-quality, contaminant-free biopharmaceutical products. Consequently, the pursuit of effective viral inactivation solutions is essential to address these challenges and ensure the safe development of cutting-edge medical advancements.
Restraints in the Global Viral Inactivation Market
The viral inactivation market faces significant restraints due to the complex regulatory environment that governs the pharmaceutical and biotechnology industries. The stringent and constantly changing requirements established by regulatory bodies like the FDA and EMA complicate the navigation for businesses in this field. Companies are often required to conduct extensive validation studies and maintain rigorous documentation to prove the efficacy of their viral inactivation techniques, which can be both time-intensive and costly. This intricate regulatory landscape can hinder market growth and innovation by placing additional burdens on companies as they strive to meet compliance standards.
Market Trends of the Global Viral Inactivation Market
The Global Viral Inactivation market is experiencing a robust upward trend, propelled by the surge in biopharmaceutical manufacturing, particularly with the rise of monoclonal antibodies, gene therapies, and cell-based therapies. As these innovative biologics become essential for tailored therapeutic approaches, there is an increasing imperative for enhanced viral safety protocols to mitigate contamination risks. This demand is catalyzing the adoption of advanced viral inactivation techniques, reflecting a broader industry transition towards cutting-edge treatment modalities and the integration of sophisticated technologies. Consequently, this trend is significantly contributing to the market's expansion, signaling a pivotal evolution in biopharmaceutical safety standards and practices.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Viral Inactivation Market Size by Method & CAGR (2025-2032)
- Market Overview
- Solvent Detergent Method
- Pasteurization
- Other Viral Inactivation Method
Global Viral Inactivation Market Size by Product & CAGR (2025-2032)
- Market Overview
- Kits and Reagents
- Services
- Viral Inactivation Systems and Accessories
Global Viral Inactivation Market Size by Application & CAGR (2025-2032)
- Market Overview
- Blood & Blood Products
- Cellular & Gene Therapy Products
- Stem Cell Products
- Tissue & Tissue Products
- Vaccines and Therapeutics
Global Viral Inactivation Market Size by End User & CAGR (2025-2032)
- Market Overview
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Other End Users
Global Viral Inactivation Market Size & CAGR (2025-2032)
- North America (Method, Product, Application, End User)
- Europe (Method, Product, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Method, Product, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Method, Product, Application, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Method, Product, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Parker Hannifin Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mettler-Toledo International Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SGS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE HealthCare Technologies Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cerus Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Terumo BCT, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific SE (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Macopharma SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kedrion S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rad Source Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
